Welcome to our dedicated page for ZIMVIE news (Ticker: ZIMV), a resource for investors and traders seeking the latest updates and insights on ZIMVIE stock.
ZimVie Inc (ZIMV) delivers innovative dental and spine solutions through advanced biomaterials and digital workflow integration. This news hub provides investors and medical professionals with centralized access to official updates spanning product developments, financial disclosures, and strategic initiatives.
Track announcements across ZimVie's core segments: dental innovations like implant surface technologies and CAD/CAM restorative systems, plus spine surgery advancements in fusion devices and surgical instrumentation. Receive timely updates on regulatory milestones, partnership agreements, and clinical research outcomes.
Our curated news collection enables efficient monitoring of ZimVie's progress in merging digital planning tools with medical device engineering. Discover updates on RealGUIDE® software enhancements, biomaterial research breakthroughs, and market expansion strategies while maintaining compliance with financial disclosure standards.
Bookmark this page for structured access to ZimVie's evolving position in life sciences. Combine technical insights with corporate updates to inform your analysis of this dual-segment medical technology innovator.
ZimVie Inc. (ZIMV) reported Q3 2024 financial results with third-party net sales of $103.2 million, showing a 2.0% decrease from Q3 2023. The company posted a net loss of $(3.0) million, improving from a $(10.2) million loss in the previous year. Adjusted EBITDA reached $13.1 million with a 12.7% margin, up 110 basis points year-over-year. The company reported GAAP diluted EPS of $(0.11) and adjusted diluted EPS of $0.12. ZimVie updated its full-year 2024 guidance, projecting net sales between $450M to $455M and adjusted EBITDA between $60M to $62M.
ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental market, has announced its participation in the upcoming UBS Global Healthcare Conference. The company's management will deliver a presentation on Tuesday, November 12, 2024, at 3:30 p.m. Eastern Time / 12:30 p.m. Pacific Time.
Interested parties can access both the live webcast and an archived recording of the presentation through ZimVie's investor website at investor.zimvie.com.
ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental market, has announced that it will report its third quarter 2024 financial results after market close on Wednesday, October 30, 2024. The company will host a conference call to discuss the results, beginning at 4:30 p.m. Eastern Time on the same day.
Interested parties can register for the conference call online. It is recommended to register more than 15 minutes before the call starts. For those unable to attend the live call, a replay of the webcast will be made available on the company's investor relations website at investor.zimvie.com.
ZimVie Inc. (ZIMV) reported Q2 2024 financial results for its continuing operations in the dental market. Key highlights include:
- Third party net sales of $116.8 million, down 1.5% year-over-year
- Net loss of $(9.6) million, with a net loss margin of 8.2%
- Adjusted EBITDA of $16.1 million, with a 13.8% margin
- Reduced debt to $235.1 million
- Cash balance of $78.6 million
The company reaffirmed its full-year 2024 guidance, projecting net sales of $450-$460 million, adjusted EBITDA of $60-$65 million, and adjusted EPS of $0.55-$0.70. CEO Vafa Jamali highlighted progress in customer engagement, product innovation, and operational improvements.
ZimVie Inc. (Nasdaq: ZIMV) has released RealGUIDE® 5.4, an update to its dental implant software suite. This latest version introduces new features designed to enhance provider efficiency and cost savings. Key improvements include:
1. One-click nerve detection and automated bone and tooth segmentation for faster complex case planning and improved risk management.
2. New restorative design workflows to meet evolving clinic and dental laboratory needs.
3. Amplified CAD workflows for creating attractive implant dentistry designs.
4. Automated 'split-bar' toolset for efficient creation of complex multi-material prostheses.
5. Cloud-based design libraries for improved accessibility.
The update aims to make guided surgery the standard for all implant cases, potentially increasing implant dentistry adoption.
ZimVie Inc. (Nasdaq: ZIMV) has announced the U.S. launch of its GenTek® Genuine Restorative Components product portfolio, following FDA 510(k) clearance. This launch expands ZimVie's end-to-end prosthetic offerings in the dental market. The GenTek portfolio, first introduced in Europe in 2019, includes Ti-Bases, pre-milled abutment blanks, screws, instruments, and ancillary products for digitally driven CAD/CAM restorations.
Designed to mate with ZimVie implant systems, GenTek components ensure a perfect fit and tight seal for long-term aesthetic and functional restorations. The company anticipates strong demand in the U.S. market, following the product's success in Europe.
ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental market, has announced that it will report its second quarter 2024 financial results after market close on Thursday, August 1, 2024. The company management will host a conference call at 4:30 p.m. Eastern Time on the same day to discuss the results. Interested parties can register for the call online, with registration recommended more than 15 minutes before the call starts. A replay of the webcast will be available on the company's investor relations website.
On May 16, 2024, ZimVie, a global leader in the dental market, announced its participation in two upcoming investor conferences. The company will present at the Stifel 2024 Jaws & Paws Conference on May 30, 2024, at 11:30 a.m. Eastern Time, and at the 45th Annual Goldman Sachs Global Healthcare Conference on June 12, 2024, at 3:20 p.m. Eastern Time. Interested parties can access a live webcast of these presentations through the 'Investors' section on ZimVie's website.
ZimVie Inc. (Nasdaq: ZIMV) reported third party net sales of $118.2 million, a net loss of ($11.5) million, and an adjusted EBITDA of $12.5 million for the first quarter of 2024. The company completed the sale of its spine business for $375 million, repaid $275 million of debt, and is now focusing on its dental market leadership.
FAQ
What is the current stock price of ZIMVIE (ZIMV)?
What is the market cap of ZIMVIE (ZIMV)?
